AmitisGen TECH Dev Group Personalized and Precision Medicine Journal 3115-7874 10 37 2025 06 22 Pharmacogenomics: Unlocking the Future of Personalized Medicine and Precision Drug Development 39 47 724143 10.22034/pmj.2025.2049550.1050 EN Sanaz Khosravi Ghareh Cheh Assistant doctor, Neurology Department, 93413 Cham, Germany. Journal Article 2025 01 22 Pharmacogenomics is a relatively new subject that utilizes genomics and pharmacology to investigate the ways in which genetic variants influence individual responses to treatment with pharmaceuticals. A departure from the conventional "one-size-fits-all" treatment strategy is marked by the advent of pharmacogenomics, which makes it possible to tailor pharmacological regimens to the specific genetic profile of an individual. Significant improvements in pharmacological efficacy, reductions in adverse drug reactions (ADRs), and assistance in the development of drugs that are both safe and effective for a wide range of conditions are all possible outcomes of this domain. The purpose of this study is to investigate the prospective results of pharmacogenomics, with a particular emphasis on the function it plays in the process of drug development and its incorporation into personalized medicine. The purpose of this study is to investigate the genetic characteristics that influence the metabolism, efficacy, and toxicity of drugs, as well as to investigate the regulatory framework that is associated with pharmacogenomics testing. This paper provides a synopsis of the most important genes that are involved in pharmacogenomic responses, as well as a discussion of the potential difficulties that may arise in their practical use and the anticipated breakthroughs in this area of study. https://www.pmjournal.ir/article_724143_bcebe34a7f47c00e98d7ea5c844ba2ee.pdf